 MONT-SAINT-GUIBERT, Belgium, June 10, 2020 GLOBE NEWSWIRE -- Celyad SA Euronext Nasdaq: CYAD, clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced the launch of its corporate rebranding, including changing its name to Celyad Oncology. The new name highlights the Companys significant progress with its next-generation CAR T programs and emphasizes its commitment to cancer patients. 